NEWS
Stocktwits Top 25 - Week 09

Welcome to the Stocktwits Top 25 Newsletter for Week 09 of 2024!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date (YTD) and tracks their performances over time. 

Here are the Stocktwits Top 25 Lists for Week 09:

P.S. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

S&P 500
ST Top 25 S&P 500

The S&P 500 Top 25 list (+5.94%) outperformed the S&P 500 index (+0.95%).

There were 8 major changes to the list this week.

Check out how the momentum meter has performed vs. the S&P 500 index this year:

NASDAQ 100
The Large-Cap Nasdaq 100

The Nasdaq 100 Top 25 list (+5.92%) outperformed the Nasdaq 100 index (+2.04%).

There were 2 major changes to the list this week.

RUSSELL 2000
The Growth-Centric Russell 2000

The Russell 2000 Top 25 list (+32.17%) outperformed the Russell 2000 index (+2.96%).

There were 7 major changes to the list this week.

Top Dawg Of The Week 🐶

The Top 25 lists' Top Dawg was Janux Therapeutics, which rallied 203.82%. 📈

The small-cap biotech stock soared this week after unveiling promising results for a prostate cancer treatment. Notably, there were no serious incidents of cytokine release syndrome (CRS). This condition is an acute, but temporary and treatable, immune system response that occurs with certain cancer treatments. 💊

That news attracted several analyst upgrades, helping boost the stock to all-time highs. 📝

$JANX is up 344.27% YTD.

Get In Touch

Have feedback on The Daily Rip? Shoot me (Tom Bruni) an email at [email protected]; I’d love to hear from you.

Want to sponsor this newsletter and reach hundreds of thousands of passionate investors and traders? Reach us here.

Disclaimer: Content, news, research, tools, and securities symbols are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here.